• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

Cortisporin Use in Routine Tympanoplasty

by Larry Lundy, MD • March 1, 2014

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

Is it safe to use commercially available polymyxin B, neomycin, and hydrocortisone suspension in routine tympanoplasty?

Background: Over the last couple of decades, there have been questions regarding the use of polymyxin B, neomycin, and hydrocortisone suspension (PNH, Cortisporin, Alcon Manufacturing) in tympanoplasty, specifically regarding potential ototoxicity of neomycin. In 2004, an AAO-HNS–sponsored consensus panel published an evidence-based literature review specifically addressing the potential ototoxicity of topical drops in the middle ear. They recommended use of ototoxic drops only if no non-ototoxic drops are available as an alternative and only in infected ears.

You Might Also Like

  • Best Practice in Tympanoplasty
  • Limited Histopathology Adequate for Evaluating Routine Cholesteatoma Cases
  • A Longer Shelf Life for Antimicrobial Ear Drops
  • FDA Warns Against Use of Unapproved Ear Drops in Children
Explore This Issue
March 2014

Study design: Case series with chart review.

Setting: Private practice.

Synopsis: The authors of this current study have not clinically witnessed ototoxicity related to PNH. Therefore, they undertook a retrospective chart review of their type I tympanoplasties. Over a 10-year period, 272 ears met their criteria: tympanoplasty only, ears excluded for incomplete follow-up, incomplete audiograms, and drilling (i.e., lateral grafts). The patient age range was 3 to 79 years, with 24.4 years the average age and 15 years the median age, indicating a preponderance of pediatric patients. In each patient, Gelfoam soaked with PNH was used to fill the middle ear and ear canal to support the graft. A post-operative audiogram no sooner than four months was obtained and then compared with pre-operative audiograms. There was no significant change in the audiometric thresholds (500, 1000, 2000, 3000, and 4000 Hz). While recognizing the limitations of their study, the authors concluded that there is grade B evidence that Cortisporin suspension shows no evidence of cochlear ototoxicity when used in tympanoplasty surgery.

Bottom line: Cortisporin use in routine tympanoplasty does not cause cochlear ototoxicity.

Citation: House JR III, House LK. Ototoxicity of polymyxin B, neomycin, and hydrocortisone suspension in tympanoplasty surgery. Otolaryngol Head Neck Surg. 2014;150:282-284.

Filed Under: Literature Reviews, Otology/Neurotology, Otology/Neurotology, Practice Focus Tagged With: tympanoplastyIssue: March 2014

You Might Also Like:

  • Best Practice in Tympanoplasty
  • Limited Histopathology Adequate for Evaluating Routine Cholesteatoma Cases
  • A Longer Shelf Life for Antimicrobial Ear Drops
  • FDA Warns Against Use of Unapproved Ear Drops in Children

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Would you choose a concierge physician as your PCP?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • A Journey Through Pay Inequity: A Physician’s Firsthand Account

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • Excitement Around Gene Therapy for Hearing Restoration
    • “Small” Acts of Kindness
    • How To: Endoscopic Total Maxillectomy Without Facial Skin Incision
    • Science Communities Must Speak Out When Policies Threaten Health and Safety
    • Observation Most Cost-Effective in Addressing AECRS in Absence of Bacterial Infection

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939